65,437 trials
Non-small Cell Lung Carcinoma
Primary: Part 2 Cohorts G+ and G-: Objective Response Rate (ORR) — 55.0; 28.6 Percentage of Participants — p=0.0016
Sleep Disorder · Stage IA Breast Cancer · Stage IB Breast Cancer
Primary: Percentage of Eligible Patients Consented — 77.17 percentage of participants — p=>0.9999
Schizophrenia · Cigarette Smoking
Primary: Cotinine Level — 257.9; 258.6; 176.0; 252.1 cotinine ng/ml
Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma
Primary: Overall Survival — 8.9; 7.6 months
Carpal Tunnel Syndrome
Primary: Change in SSS of the BCTQ at 28 Days vs Baseline — 0.59; 0.93; .00 point decrease in SSS
Pediatric Distal Radius Fractures
Primary: Number of Participants Without Fracture Displacement at 8 Weeks Post Injury — 26; 27 Participants
Breast Cancer
Primary: Correlation of Vitamin D Levels, Prognostic Factors, and Gene Expression Profile in Patients With Breast Cancer — 0; 0; 0; 0 percentage of participants
Malaria · HIV Infections
Primary: Prevalence of Malaria Defined as Positive Placental Blood Smear — 5; 6 participants — p=.76
Postpartum Period
Primary: Mirena in Place — 10; 3 participants
MDS · Immunodeficiency · GATA2
Primary: Days to Neutrophil Engraftment — 12 Days
Healthy
Primary: Maximal Mean ΔΔQTcF — 5.0; 23.4; 0.8; 12.3 milliseconds
Pulmonary Hypertension
Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04
Autonomic Nervous System · Baroreflex · Stress, Physiological
Primary: Cardiovagal Baroreflex Sensitivity (Modified Oxford Technique) — 17.75; 16.90; 14.42; 17.27 ms/mmHg
Influenza, Human
Primary: Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT) — 3.80; 3.77; 5.72; 5.70 Titers
Knee Pain Arthritis
Primary: Change in Blood Serum Levels of Bupivocaine From Baseline — 0.6; 0.95; 0.8 ug/cc